KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) Other Operating Expenses (2020 - 2025)

Pacific Biosciences Of California (PACB) has 7 years of Other Operating Expenses data on record, last reported at -$1.9 million in Q4 2025.

  • For Q4 2025, Other Operating Expenses fell 102.09% year-over-year to -$1.9 million; the TTM value through Dec 2025 reached $347.9 million, up 85.14%, while the annual FY2025 figure was $347.9 million, 85.14% up from the prior year.
  • Other Operating Expenses reached -$1.9 million in Q4 2025 per PACB's latest filing, down from -$1.6 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $353.2 million in Q1 2025 and bottomed at -$54.8 million in Q3 2021.
  • Average Other Operating Expenses over 5 years is $31.7 million, with a median of $1.9 million recorded in 2022.
  • The widest YoY moves for Other Operating Expenses: up 15984.29% in 2025, down 360.06% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at $161.7 million in 2021, then crashed by 98.73% to $2.1 million in 2022, then soared by 72.26% to $3.5 million in 2023, then surged by 2474.49% to $91.1 million in 2024, then crashed by 102.09% to -$1.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were -$1.9 million in Q4 2025, -$1.6 million in Q3 2025, and -$1.8 million in Q2 2025.